Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 195 Church St Fl 14 NEW HAVEN CT 06510-2009 |
Tel: | 1-203-9039627 |
Website: | https://www.trevitherapeutics.com |
IR: | See website |
Key People | ||
Jennifer L. Good President, Chief Executive Officer, Director | Thomas R. Sciascia Co-Founder, Chief Science Officer | Lisa Delfini Chief Financial Officer |
David Clark Chief Medical Officer | Farrell Simon Chief Commercial Officer |
Business Overview |
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company's Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company's subsidiary is Trevi Therapeutics Limited. |
Financial Overview |
For the fiscal year ended 31 December 2023, Trevi Therapeutics Inc revenues was not reported. Net loss increased less than 1% to $29.1M., offset by Pharmaceuticals segment loss increase of 13% to $33.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.45 to -$0.29. |
Employees: | 25 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $125.44M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$33.80M as of Dec 31, 2023 |
Net annual income (TTM): | -$29.07M as of Dec 31, 2023 |
Free cash flow (TTM): | -$31.85M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 68,960,167 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |